Skip Nav Destination
Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas.
Mol Cancer Ther (2013) 12 (11_Supplement): A276.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
- Anna Richter
- Nina Schoenwaelder
- Sina Sender
- Christian Junghanss
- Claudia Maletzki
Cancers (2021) 13 (10): 2497.
- Neelima Vidula
- Hope S. Rugo
Expert Review of Anticancer Therapy (2018) 18 (1): 3.
- Yue Wang
- Yanle Zhi
- Qiaomei Jin
- Shuai Lu
- Guowu Lin
- Haoliang Yuan
- Taotao Yang
- Zhanwei Wang
- Chao Yao
- Jun Ling
- Hao Guo
- Tonghui Li
- Jianlin Jin
- Baoquan Li
- Li Zhang
- Yadong Chen
- Tao Lu
Journal of Medicinal Chemistry (2018) 61 (4): 1499.
- Dorota Kwapisz
Breast Cancer Research and Treatment (2017) 166 (1): 41.
- Richard S. Finn
- Alexey Aleshin
- Dennis J. Slamon
Breast Cancer Research (2016) 18 (1)
- Tinghan Li
- Tianwei Weng
- Minzan Zuo
- Zhihui Wei
- Ming Chen
- Zhiyu Li
Future Medicinal Chemistry (2016) 8 (17): 2047.
- Rossella Martinello
- Sofia Genta
- Danilo Galizia
- Elena Geuna
- Andrea Milani
- Giorgia Zucchini
- Giorgio Valabrega
- Filippo Montemurro
Expert Opinion on Pharmacotherapy (2016) 17 (16): 2179.
- Yi-Xiang Zhang
- Ewa Sicinska
- Jeffrey T. Czaplinski
- Stephen P. Remillard
- Samuel Moss
- Yuchuan Wang
- Christopher Brain
- Alice Loo
- Eric L. Snyder
- George D. Demetri
- Sunkyu Kim
- Andrew L. Kung
- Andrew J. Wagner
Molecular Cancer Therapeutics (2014) 13 (9): 2184.
- Mark A. Dickson
Clinical Cancer Research (2014) 20 (13): 3379.
- Gabriela Torres
- Isabel Echavarría
- Miriam Lobo
- Ivan Márquez-Rodas
- Miguel Martin
Current Breast Cancer Reports (2014) 6 (2): 79.
RSS Feeds